S2212 SHORTER ANTHRACYCLINE-FREE CHEMO IMMUNOTHERAPY ADAPTED TO PATHOLOGICAL RESPONSE IN EARLY TRIPLE NEGATIVE BREAST CANCER (SCARLET) A RANDOMIZED PHASE III STUDY

Brief description of study

This study is for patients with early-stage triple-negative breast cancer (TNBC). The study team wants to compare two kinds of treatments, one with a drug called anthracycline and another without it, but both using another drug called pembrolizumab. The study team is checking if the treatment without anthracycline is just as effective as the one with it, especially in terms of how long patients stay free of cancer events. The study team is also looking at how patients feel during and after the treatment concerning side effects. Additionally, the study team is studying something called tumor-infiltrating lymphocytes (TILs) to make sure the treatment works for everyone. This part of the study will help the study team understand the outcomes based on the amount of TILs in the tumors. Overall, the goal is to find the most effective treatment with few side effects for patients with TNBC.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.